Table 1 Tumor spectrum analysis of PER2S662G2H:p53R172H/+, PER2S662D2H:p53R172H/+and p53R172H/+ mice
From: The circadian mutation PER2S662G is linked to cell cycle progression and tumorigenesis
Tumor types | p53 R172H | PER2 S662G2H :p53 R172H | PER2 S662D2H :p53 R172H |
|---|---|---|---|
Lymphoma | 13/46 (28.2%) | 6/33 (18.2%) | 7/31 (22.6%) |
Osteosarcoma | 14/46 (36.1%) | 10/33 (30.3%) | 9/31 (29.0%) |
Fibrosarcoma | 7/46 (15.2%) | 3/33 (9.1%) | 5/31 (16.1%) |
Liver tumors | 4/46 (8.7%) | 9/33 (27.3%) | 6/31 (19.4%) |
Unknown | 2/46 (4.3%) | 2/33 (6.1%) | 4/31 (12.9%) |
Multiple tumors | 4/46 (8.7%) | 2/33 (6.1%) | 4/31 (12.9%) |
Metastasis | 8/46 (17.4%) | 5/33 (15.2%) | 4/31 (12.9%) |
